Statistics for Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
Total visits
| views | |
|---|---|
| Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2 | 3 |
Total visits per month
| views | |
|---|---|
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 3 |
Top country views
| views | |
|---|---|
| United States | 2 |
| Mexico | 1 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |
| Mexico City | 1 |